[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100489720":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":32,"responsibleParty":52,"collaborators":54,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":24,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":24,"overallStatus":35,"whyStopped":24,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"University Health Network, Toronto","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1 - Investigational","EXPERIMENTAL","Radiation treatment (36 Gy in 6 fractions) to be delivered every other day over 2 weeks (excluding weekends).",[13],"Radiation: Radiotherapy",{"label":15,"type":6,"description":16,"interventionNames":17},"Arm 2 - Standard","Radiation treatment (36 Gy in 6 fractions) to be delivered once a week over 6 weeks.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"RADIATION","Radiotherapy","Standard of care radiotherapy administered as per institutional guidelines.",[9,15],null,[26],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Peter Chung, MD","CONTACT","416-946-4501","2126","peter.chung@rmp.uhn.ca",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"University Health Network, Princess Margaret Hospital","RECRUITING","Toronto","Ontario","M5G 2M9","Canada","CA",{"type":42,"coordinates":43},"Point",[44,45],-79.39864,43.70643,{"lat":45,"lon":44},[48,50],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":49},"peter.chung@uhn.ca",{"name":27,"role":51,"phone":24,"phoneExt":24,"email":24},"PRINCIPAL_INVESTIGATOR",{"type":53,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[55],{"name":56,"class":57},"TerSera Therapeutics LLC","INDUSTRY","100489720","phase-2-consolidative-prostate-radiotherapy-in-metastatic-prostate-cancer-100489720",false,"NCT05656794","Consolidative Prostate Radiotherapy in Metastatic Prostate Cancer","Consolidative Prostate Radiotherapy in Patients With Metastatic Prostate Cancer","CONSORT-PC","Inclusion Criteria:\n\n* Histologically-proven prostate cancer\n* Presence of low-volume or high-volume metastases (high volume defined as the presence of visceral metastases or ≥4 bone lesions with at least 1 lesion beyond the vertebral bodies and pelvis.)\n* Planned to or receiving systemic treatment ADT +\u002F- ARAT as per physician discretion (Previous chemotherapy allowed if completed more than 6 weeks prior to randomization.)\n* Planned for EBRT\n* ECOG 0 or 1\n* Age 18 years or older\n\nExclusion Criteria:\n\n* Prior radiotherapy to pelvis\n* Active ulcerative colitis or Crohn's Disease, at discretion of treating physician\n* Any condition where radiotherapy is contraindicated","MALE","18 Years","100 Years",{"count":70,"type":71},40,"ESTIMATED","INTERVENTIONAL",[74],"PHASE2","This is a prospective, randomized phase II trial investigating if radiation treatment delivered every other day for 2 weeks has the same side effects as radiation treatment delivered once weekly for 6 weeks.",[77],"Prostate Metastases","2026-03-18",{"date":80,"type":81},"2026-03-23","ACTUAL",{"date":83,"type":81},"2023-08-09",{"date":85,"type":71},"2031-08",{"name":5,"class":6},1]